Papers matching “eculizumab” in Complement system in diseases 68
Not finding it? Sign in to also search OpenAlex live.
-
Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study2022 Kidney International Reports article Immunology and Microbiology Complement system in diseases Open access
Romy N. Bouwmeester, Caroline Duineveld, Kioa Lente Wijnsma, Fréderike J. Bemelman, Joost W van der Heijden, Joanna A.E. van Wijk, +20 more
50citations -
Plain Language Summary of PEGASUS, a Study Comparing Pegcetacoplan with Eculizumab for 16 Weeks in People with Paroxysmal Nocturnal Hemoglobinuria2023 Future Rare Diseases article Immunology and Microbiology Complement system in diseases Open access
Morag Griffin, Jeff Szer, Ilene Ceil Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, +11 more
0citations -
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria2021 New England Journal of Medicine article Immunology and Microbiology Complement system in diseases Open access cited by 1 patent
Peter Hillmen, Jeff Szer, Ilene Ceil Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, +11 more
407citations -
Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation2023 Kidney International Reports article Immunology and Microbiology Complement system in diseases Open access
Caroline Duineveld, Romy N. Bouwmeester, Kioa Lente Wijnsma, Fréderike J. Bemelman, Joost W van der Heijden, Stefan P. Berger, +14 more
21citations -
One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab2020 European Journal Of Haematology article Immunology and Microbiology Complement system in diseases Open access
Austin Gladston Kulasekararaj, Anita Hill, Saskia M. C. Langemeijer, Richard A. Wells, Fernando Ataúlfo González Fernández, Anna Gayà, +12 more
36citations -
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria2024 American Journal of Hematology article Immunology and Microbiology Complement system in diseases Open access
Phillip Scheinberg, Diego V. Clé, Jin Seok Kim, Erfan Nur, Mustafa Nuri Yenerel, Wilma Barcellini, +15 more
52citations -
Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors
Jens Panse, Nicolas Daguindau, Sonia Okuyama, Régis Peffault de Latour, Philippe Schafhausen, Nicole Straetmans, +3 more
3citations -
Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Caroline Irene Piatek, Jong Wook Lee, Morag Griffin, J Nishimura, Christopher Jordan Patriquin, Hubert Schrezenmeier, +9 more
2citations -
Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
Régis Peffault de Latour, Alexander Roeth, Austin Gladston Kulasekararaj, Phillip Scheinberg, Yasutaka Ueda, Carlos M. de Castro, +15 more
23citations -
S183: PHASE III RANDOMIZED, MULTICENTER, OPEN-LABEL COMMODORE 1 TRIAL: COMPARISON OF CROVALIMAB VS ECULIZUMAB IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Phillip Scheinberg, Diego V. Clé, Valentina Giai, Marek Hus, Jin Seok Kim, Cristina Barrenetxea Lekue, +11 more
5citations -
Patient-Reported Outcomes (PROs) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Eculizumab: Results from the Phase III Randomized COMMODORE 2 and COMMODORE 1 Trials
Jens Panse, Jaroslav Čermák, Olena Kyselova, Akihiko Gotoh, Fahri Şahin, Hubert Schrezenmeier, +3 more
4citations -
Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Phillip Scheinberg, Diego V. Clé, Bérangère Devalet, Valentina Giai, Cristina Barrenetxea Lekue, Hsuan‐Yu Lin, +12 more
0citations -
Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis2023 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Caroline Irene Piatek, Jong Wook Lee, Morag Griffin, Jun‐ichi Nishimura, Christopher Jordan Patriquin, Hubert Schrezenmeier, +9 more
0citations -
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial2022 The Lancet Haematology article Immunology and Microbiology Complement system in diseases Open access
Régis Peffault de Latour, Jeff Szer, Ilene Ceil Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, +12 more
74citations -
Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study2022 Bone Marrow Transplantation article Immunology and Microbiology Complement system in diseases Open access
Peter Švec, Reem Elfeky, Jacques‐Emmanuel Galimard, Christine S. Higham, Arnaud Dalissier, Troy C. Quigg, +30 more
20citations -
RESULTS OF THE PEGASUS PHASE 3 RANDOMIZED TRIAL DEMONSTRATING SUPERIORITY OF THE C3 INHIBITOR PEGCETACOPLAN COMPARED TO ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA2020 Hematology Transfusion and Cell Therapy article Immunology and Microbiology Complement system in diseases Open access
Peter Hillmen, Jeff Szer, Britta Höchsmann, Jens Panse, Jean‐Jacques Kiladjian, Carlos M. DeCastro, +7 more
3citations -
CT-286: Results of the PEGASUS Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria2020 Clinical Lymphoma Myeloma & Leukemia conference-abstract Immunology and Microbiology Complement system in diseases
Peter Hillmen, Jeff Szer, Ilene Ceil Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, +10 more
1citations -
MDS-134: Efficacy and Safety at 48 Weeks of Pegcetacoplan in Adult Paroxysmal Nocturnal Hemoglobinuria Patients with Suboptimal Response to Prior Eculizumab Treatment2021 Clinical Lymphoma Myeloma & Leukemia conference-abstract Immunology and Microbiology Complement system in diseases
Ilene Ceil Weitz, Régis Peffault de Latour, Jeff Szer, Alexander Röth, Britta Höchsmann, Jens Panse, +12 more
0citations -
Poster: MDS-134: Efficacy and Safety at 48 Weeks of Pegcetacoplan in Adult Paroxysmal Nocturnal Hemoglobinuria Patients with Suboptimal Response to Prior Eculizumab Treatment2021 Clinical Lymphoma Myeloma & Leukemia article Immunology and Microbiology Complement system in diseases
Ilene Ceil Weitz, Régis Peffault de Latour, Jeff Szer, Alexander Röth, Britta Höchsmann, Jens Panse, +12 more
0citations -
The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Randomized Phase III APPLY-PNH Trial
Régis Peffault de Latour, Austin Gladston Kulasekararaj, Phillip Scheinberg, Yutaka Ueda, Carlos de Castro, Samopriyo Maitra, +3 more
1citations